Skip to main content
Journal ArticleOPEN ACCESS

Should FOLFOXIRI Plus Bevacizumab Be the Standard First-Line Therapy in Metastatic Colorectal Cancer?

  • Nipp R
  • Ryan D
The Oncologist (2015) 20(3) 236-238
DOI: 10.1634/theoncologist.2014-0495
5Citations
Citations of this article
38Readers
Mendeley users who have this article in their library.

Abstract

The TRIBE trial compared the FOLFOXIRI regimen plus bevacizumab with FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer. FOLFOXIRI plus bevacizumab is an acceptable therapeutic option, but the results of the TRIBE trial do not establish this regimen as the best treatment option for patients with metastatic colorectal cancer.

Cite

CITATION STYLE

APA

Nipp, R. D., & Ryan, D. P. (2015). Should FOLFOXIRI Plus Bevacizumab Be the Standard First-Line Therapy in Metastatic Colorectal Cancer? The Oncologist, 20(3), 236–238. https://doi.org/10.1634/theoncologist.2014-0495

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free